Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 5635929, 10 pages
https://doi.org/10.1155/2017/5635929
Research Article

Anti-Interleukin-22-Neutralizing Antibody Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Mice

1Department of Cardiology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
2Department of Cardiology, Hubei Key Laboratory of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China
3Emergency & Critical Care Center, Beijing Institute of Heart, Lung, and Blood Vessel Diseases and Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

Correspondence should be addressed to Yingzhong Lin; moc.621@nilgnohzgniy and Jun Wan; moc.621@3691nujnaw

Received 23 April 2017; Revised 5 September 2017; Accepted 12 September 2017; Published 22 November 2017

Academic Editor: Shin-ichi Yokota

Copyright © 2017 Jing Ye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Sun, R. Huo, Y. Sheng et al., “Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy,” Hypertension, vol. 61, no. 2, pp. 352–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Lu, J. Xing, X. Zhang et al., “Exogenous hydrogen sulfide prevents cardiomyocyte apoptosis from cardiac hypertrophy induced by isoproterenol,” Molecular and Cellular Biochemistry, vol. 381, no. 1-2, pp. 41–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. H. van Berlo, M. Maillet, and J. D. Molkentin, “Signaling effectors underlying pathologic growth and remodeling of the heart,” The Journal of Clinical Investigation, vol. 123, no. 1, pp. 37–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Gjesdal, D. A. Bluemke, and J. A. Lima, “Cardiac remodeling at the population level—risk factors, screening, and outcomes,” Nature Reviews Cardiology, vol. 8, no. 12, pp. 673–685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Dudakov, A. M. Hanash, and M. R. M. van den Brink, “Interleukin-22: immunobiology and pathology,” Annual Review of Immunology, vol. 33, no. 1, pp. 747–785, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Basu, D. B. O'Quinn, D. J. Silberger et al., “Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria,” Immunity, vol. 37, no. 6, pp. 1061–1075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Andoh, Z. B. Zhang, O. Inatomi et al., “Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts,” Gastroenterology, vol. 129, no. 3, pp. 969–984, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Ikeuchi, T. Kuroiwa, N. Hiramatsu et al., “Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1037–1046, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Liang, J. Wang, H. Chu et al., “Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis,” Mediators of Inflammation, vol. 2013, Article ID 209179, pp. 1–11, 2013. View at Publisher · View at Google Scholar
  10. A. G. Besnard, R. Sabat, L. Dumoutier et al., “Dual role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 9, pp. 1153–1163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. Kong, W. Wu, F. Yang et al., “Increased expressions of IL-22 and Th22 cells in the coxsackievirus B3-induced mice acute viral myocarditis,” Virology Journal, vol. 9, no. 1, pp. 232–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Q. Kong, Y. Xue, W. Wu et al., “IL-22 exacerbates the severity of CVB3-induced acute viral myocarditis in IL-17A-deficient mice,” Molecular Medicine Reports, vol. 7, no. 4, pp. 1329–1335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Rattik, K. Hultman, U. Rauch et al., “IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice,” Atherosclerosis, vol. 242, no. 2, pp. 506–514, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Gangemi, P. Parisi, L. Ricciardi et al., “Is interleukin-22 a possible indicator of chronic heart failure’s progression?” Archives of Gerontology and Geriatrics, vol. 50, no. 3, pp. 311–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Li, H. X. Wang, Q. Y. Han et al., “Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP,” Journal of Molecular and Cellular Cardiology, vol. 79, pp. 303–314, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. C. C. Zhou, S. Ahmad, T. Mi et al., “Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy,” Circulation Research, vol. 100, no. 1, pp. 88–95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Q. Shang, J. J. Yu, L. Y. Zhu et al., “Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells,” American Journal of Translational Research, vol. 7, no. 10, pp. 1782–1797, 2015. View at Google Scholar
  18. S. Wang, Y. Li, J. Fan et al., “Interleukin 22 ameliorated renal injury and fibrosis in diabetic nephropathy though inhibition of NLRP3 inflammasome activation,” Cell Death & Disease, vol. 8, no. 7, p. e2937, 2017. View at Publisher · View at Google Scholar
  19. G. F. Weber, S. Schlautkotter, S. Kaiser-Moore, F. Altmayr, B. Holzmann, and H. Weighardt, “Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis,” Infection and Immunity, vol. 75, no. 4, pp. 1690–1697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. L. Simonian, F. Wehrmann, C. Roark, W. K. Born, R. L. O'Brien, and A. P. Fontenot, “γδ T cells protect against lung fibrosis via IL-22,” The Journal of Experimental Medicine, vol. 207, no. 10, pp. 2239–2253, 1010. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Wu, S. Liu, Y. Liu et al., “Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C,” Clinical Immunology, vol. 158, no. 1, pp. 77–87, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. B. L. Hu, C. Shi, R. E. Lei et al., “Interleukin-22 ameliorates liver fibrosis through miR-200a/beta-catenin,” Scientific Reports, vol. 6, no. 1, article 36436, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. M. B. Khawar, F. Azam, N. Sheikh, and M. K. Abdul, “How does interleukin-22 mediate liver regeneration and prevent injury and fibrosis?” Journal of Immunology Research, vol. 2016, Article ID 2148129, 8 pages, 2016. View at Publisher · View at Google Scholar
  24. E. E. Creemers and Y. M. Pinto, “Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart,” Cardiovascular Research, vol. 89, no. 2, pp. 265–272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Guo, W. Wu, Z. Cen, X. Li, Q. Kong, and Q. Zhou, “IL-22-producting Th22 cells play a protective role in CVB3-induced chronic myocarditis and dilated cardiomyopathy by inhibiting myocardial fibrosis,” Virology Journal, vol. 11, no. 1, p. 230, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Chiu, B. Wang, and K. Shyu, “Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes,” Journal of Endocrinology, vol. 220, no. 3, pp. 233–246, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. F. A. Zouein, C. Zgheib, S. Hamza et al., “Role of STAT3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking STAT3 serine 727 phosphorylation,” Hypertension Research, vol. 36, no. 6, pp. 496–503, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Frey and E. N. Olson, “Cardiac hypertrophy: the good, the bad and the ugly,” Annual Review of Physiology, vol. 65, no. 1, pp. 45–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. G. E. Gonzalez, N. E. Rhaleb, M. A. D'Ambrosio et al., “Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension,” Journal of Hypertension, vol. 33, no. 1, pp. 144–152, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Marko, H. Kvakan, J. Park et al., “Interferon-γ signaling inhibition ameliorates angiotensin II-induced cardiac damage,” Hypertension, vol. 60, no. 6, pp. 1430–1436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Liu, X. Wang, W. Feng et al., “Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats,” Experimental and Molecular Pathology, vol. 91, no. 1, pp. 362–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Sriramula and J. Francis, “Tumor necrosis factor-alpha is essential for angiotensin II-induced ventricular remodeling: role for oxidative stress,” PloS One, vol. 10, no. 9, article e0138372, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Sonnenberg, L. Fouser, and D. Artis, “Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22,” Nature Immunology, vol. 12, no. 5, pp. 383–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. V. Kamat, S. R. Thabet, L. Xiao et al., “Renal transporter activation during angiotensin-II hypertension is blunted in interferon-γ−/− and interleukin-17A−/− mice,” Hypertension, vol. 65, no. 3, pp. 569–576, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. M. S. Madhur, H. E. Lob, L. A. McCann et al., “Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction,” Hypertension, vol. 55, pp. 500–507, 2015. View at Google Scholar